FY2025 EPS Estimates for Zai Lab Cut by Cantor Fitzgerald

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings estimates for Zai Lab in a research note issued to investors on Tuesday, July 1st. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($0.95) per share for the year, down from their previous forecast of ($0.94). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab’s FY2026 earnings at $0.30 EPS.

ZLAB has been the topic of several other reports. Scotiabank initiated coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, March 13th. Leerink Partners set a $75.00 price objective on shares of Zai Lab and gave the company an “outperform” rating in a research note on Monday, June 30th. Finally, Wall Street Zen cut shares of Zai Lab from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.28.

Zai Lab Price Performance

ZLAB opened at $36.43 on Thursday. Zai Lab has a one year low of $16.01 and a one year high of $44.34. The company’s 50 day simple moving average is $33.80 and its 200-day simple moving average is $31.38. The stock has a market capitalization of $4.05 billion, a P/E ratio of -14.63 and a beta of 0.99.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. The business had revenue of $106.49 million for the quarter, compared to analysts’ expectations of $118.40 million.

Institutional Investors Weigh In On Zai Lab

Several hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new stake in Zai Lab in the first quarter worth $1,073,000. MPM Bioimpact LLC raised its holdings in Zai Lab by 4.2% in the first quarter. MPM Bioimpact LLC now owns 833,659 shares of the company’s stock worth $30,128,000 after purchasing an additional 33,659 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in Zai Lab in the first quarter worth $12,649,000. Cubist Systematic Strategies LLC raised its holdings in Zai Lab by 29.0% in the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company’s stock worth $3,384,000 after purchasing an additional 21,026 shares during the period. Finally, Royal Bank of Canada raised its holdings in Zai Lab by 214.3% in the first quarter. Royal Bank of Canada now owns 13,771 shares of the company’s stock worth $498,000 after purchasing an additional 9,390 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $28.57, for a total value of $1,428,500.00. Following the transaction, the chief executive officer directly owned 479,851 shares of the company’s stock, valued at approximately $13,709,343.07. This trade represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Lis sold 13,814 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the transaction, the director directly owned 35,106 shares in the company, valued at approximately $1,252,231.02. The trade was a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 160,155 shares of company stock valued at $4,959,535. 4.96% of the stock is currently owned by insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.